Research Paper on:
Merger Between Pharmacia and Pfizer

Unformatted Sample Text from the Research Paper:
the latter part of 2000, when powerhouse Pfizer, Inc. acquired rival Pharmacia. Because of this merger, Pfizer now has 14 drugs that are top sellers in their particular categories (Hoovers  Company Profiles, 2003). What we will try to show in this paper is that the merger has been extremely beneficial for Pfizer.  First, this is an interesting merger because it comes during a time in which the economy in general is in a downturn. As we mentioned before, the industry itself has  lightened up on mergers and acquisitions (Van Arnum, 2003). Although the pharmaceutical industry has not been impacted (although the industry is not  recession-proof, people will always need to buy drugs), things had been slowing up somewhat. Then Pfizer purchased Pharmacia, which has made the company the worlds largest research-based pharmaceutical company (Hoovers  Company Profiles, 2003). In addition to adding to Pfizers on-market drugs, the merger had also meant that Pfizers pipeline has a boost  - the company, thanks to the merger, has more than 200 projects in development including drugs for atherosclerosis, diabetes, osteoporosis, breast cancer, neuropathic pain, epilepsy, anxiety disorders, and Parkinsons Disease  (Hoovers Company Profiles, 2003) - all of which are considered diseases of concern by many Pfizer customers. In the respect of boosting  Pfizers product line, the merger has been extraordinarily successful. Additionally, the combined $7 billion research budget that this merger has yielded means that Pfizer will end up less dependent on  any one particular product (Brull et al, 2003). The merger has also made Pfizer 50 percent larger than its nearest competitor, GlaxoSmithKline